International Congress on Neuromuscular Diseases (ICNMD), 2024

Safety and efficacy of chronic weekly rozanolixizumab treatment in patients with generalised myasthenia gravis (MG0004)

Bril Vera, Grosskreutz Julian, Habib A. Ali, et al.

Ocular symptoms in patients with generalised myasthenia gravis receiving rozanolixizumab: Post hoc analysis of MycarinG

Habib A. Ali, Pascuzzi M. Robert, Vissing John, et al.

Response rates with zilucoplan in generalised myasthenia gravis: 120-week interim analysis of RAISE-XT

James F. Howard Jr., Freimer Miriam, Genge Angela, et al.

Switching to subcutaneous zilucoplan from IV C5 inhibitors in myasthenia gravis: A Phase 3b study

James F. Howard Jr., Desai Urvi, Govindarajan Raghav, et al.

Corticosteroid dose tapering with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT

M. Isabel Leite, Freimer Miriam, Genge Angela, et al.